Please login to the form below

epigenetics

This page shows the latest epigenetics news and features for those working in and with pharma, biotech and healthcare.

UK scientists begin testing BCG vaccine for severe COVID-19 protection

In the same article, the authors added that the BCG vaccine induces metabolic and epigenetic changes that enhance innate immune response to subsequent infections in a process called ‘trained immunity’.

Latest news

BMS’ oral maintenance therapy boosts survival in AML patients

We are extremely encouraged by the results of the QUAZAR AML-001 study as a part of our continuing commitment to both epigenetic research and myeloid diseases,” said Samit Hariwat, chief
RNA-focused biotech Storm Therapeutics raises extra £14m

First set up in 2015 by epigenetics and RNA specialists Professor Tony Kouzarides and Professor Eric Miska, the Cambridge-based company has a pipeline of early-stage molecules in development in ... world-leading company harnessing the power of RNA
Researchers reverse Alzheimer’s memory loss in mice

The Buffalo researchers believe their work in the developing science of epigenetics will yield answers in the elusive search for new Alzheimer's therapies. ... The researchers found that the loss of glutamate receptors resulted from an epigenetic process
GSK: we won’t be splitting up any time soon

Particularly in the spotlight is oncology, where GSK has cell therapy candidates, epigenetic modulators and antibodies targeting immune cells.
AstraZeneca to explore link between epigenetics and respiratory diseases

Epigenetics are changes in the expression of genes attributed to lifestyle factors affecting the body, but do not alter the DNA sequence. ... To date, research into epigenetics has been largely focused on cancer, but the collaborators believe it houses

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

Where next in Alzheimer’s disease R&D?

The expansion of Alzheimer’s R&D is underpinned by evidence that the disease has a range of drivers, including Abeta, inflammation and epigenetics, that evolve as it progresses. ... And a host of other academic and industry teams are looking at
Deal Watch November 2016

licence, collaboration. 207.5. Proterosos biostructures/ Merck &Co (MSD). second collaboration to develop small molecules against an additional epigenetic target for various cancers.
Deal Watch January 2016

Tensha has developed an epigenetic technology that disrupts bromodomain and extra terminal domain (BET) proteins in order to develop potential treatments for cancer. ... 535. Rodin/ Biogen. Collaboration. Multi-year neuronal epigenetics research
Deal Watch October 2015

Proteros' epigenetics technology and structure guided discovery platform for oncology targets (discovery).
Pharma deals in August 2015

This situation occurred when Genentech/Roche elected not to go further with their option to acquire the epigenetics drug discovery company, Constellation Pharmaceuticals.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

Professor Thomas Cech joins Storm Therapeutics

mature into a world leading therapeutics company targeting RNA epigenetic modulation.”.
Storm Therapeutics bolsters its team

As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells. ... Keith Blundy, chief executive officer of Storm Therapeutics,
Storm Therapeutics strengthens its board

RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. ... We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”.
Rubius Therapeutics strengthens senior team

He most recently served as the senior vice president and head of the cancer epigenetics department at GlaxoSmithKline, where he was responsible for overall strategy, as well as identification and validation ... of new epigenetic targets and advancing
Paul Stockdale joins Oxford BioDynamics as CFO

A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

SENIOR MEDICAL WRITER: Salary TBC

ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER: Salary TBC

MEDICAL WRITER - HOME WORKING: Salary TBC

SENIOR ACCOUNT MANAGER - MEDICAL COMMUNICATIONS: Salary TBC

Senior Account Director - Med Comms Agency: Salary TBC

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

PMHub

Add my company

EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

Good design saves lives: Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies: Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
A cultural shift in clinical research: Research organisations across the board are experimenting with new technologies...